Testing cell autonomy of AD phenotypes using human IPS cells

使用人类 IPS 细胞测试 AD 表型的细胞自主性

基本信息

项目摘要

DESCRIPTION (provided by applicant): Development of familial and sporadic Alzheimer's Disease (FAD and SAD) therapies requires deeper understanding of disease initiation and progression. A key unanswered question is whether all FAD and SAD neuronal misbehavior is solely the result of processes initiated or enhanced by secreted Amyloid Precursor Protein (APP) fragments such as A¿ and sAPP (and therefore cell non-autonomous), or whether A¿- independent intracellular processes driven by APP proteolytic products, e.g., the C-terminal fragment (CTF) (and therefore potentially cell autonomous) processes are a major contributor. Specifically, the major hypothesis for AD initiation and progression is the amyloid cascade hypothesis, which proposes that Ass peptide fragments of human APP are necessary and sufficient to initiate and to drive all downstream pathologies typical of AD progression including synaptic defects [1]. Alternative ideas include intracellular defects caused by presenilin or APP mutants/fragments that generate defects in endosomal or lysosomal pathways, axonal transport, neurotrophic signaling, transcriptional control, cell cycle reinitiation, oxidative defets, etc. [2-7]. There are also two-hit models in which A¿ is part of an initiating or enhancing insult n combination with intracellular insults [8-11]. These three types of models (autonomous, non-autonomous, two- hit) make distinct experimental predictions for mixed cell culture experiments using neurons derived from human induced pluripotent stem cells (hIPSC). For example, the (non-autonomous) amyloid cascade hypothesis, and related non-autonomous hypotheses based on toxicity of secreted fragments of APP (or other molecules) predict that mixtures of diseased and non-diseased neurons should cause disease phenotypes in the non-diseased neurons owing to secretion of toxic products by diseased neurons. Alternatively, in cell autonomous models of AD that do not posit secretion of toxic products, mixtures of diseased and non-diseased neurons should not lead to disease phenotypes in non-diseased neurons. Finally in two hit models, cell autonomous processes and cell nonautonomous processes might combine such that cell autonomous initiation of phenotypes might be enhanced by A¿ or other secreted toxic mediators. We propose to begin testing these ideas by further developing a new platform hIPSC human neuronal model of AD. These investigations, if successful, can shed new light on the relative contributions of autonomous and non-autonomous processes and two-hit models. We will use neurons made from hIPSC lines derived from a non-demented control patient (NDC), an FAD APPDp patient, and an SAD patient (called SAD2). We have two specific experimental aims: Aim 1) To test the hypothesis that some or all defects observed in purified neurons containing either an FAD APP duplication or a genome from an individual with SAD called SAD2 are cell-autonomous. Aim 2) To test the hypothesis that astrocytes carrying different ApoE alleles enhance or suppress AD phenotypes in purified neurons.
描述(由适用提供):家庭和零星阿尔茨海默氏病的发展(FAD和SAD)疗法需要更深入地了解疾病的启动和进展。一个关键的未解决的问题是,所有时尚和悲伤的神经元不当行为是否仅仅是由分泌的淀粉样蛋白(APP)片段(如A和Sapp)(以及单元非自治)(因此是A€)启动或增强的过程的结果自主)过程是主要贡献者。具体而言,AD主动性和进展的主要假设是淀粉样蛋白级联假设,该假设提出,人类应用程序的屁股肽片段是必需的,足以启动并驱动所有典型的AD进展的下游病理,包括突触缺陷,包括突触缺陷[1]。另类思想包括由寄生虫或APP突变体/碎片引起的细胞内缺陷,这些缺陷会在内体或溶酶体途径中产生缺陷,轴突运输,神经营养信号传导,转录控制,细胞周期重新定性,氧化缺陷等[2-7]。还有两次打击的模型,其中A是与细胞内侮辱的侮辱或增强的一部分[8-11]。这三种类型的模型(自主,非自主,两次打击)对混合细胞培养实验进行了不同的实验预测,该模型使用源自人类诱导的多能干细胞(HIPSC)的神经元进行了混合细胞培养实验。例如,基于APP(或其他分子)分泌片段的毒性(或其他分子)的毒性,(非自主)淀粉样蛋白级联假设以及相关的非自治假设预测,由于伴有不良毒性的毒性神经元的毒性神经元的毒性混合物应引起疾病表型的疾病表型,从而导致疾病的疾病表型,从而使毒性不成熟的神经元伴有毒性的分泌。另外,在不阳性分泌有毒产品的AD细胞自主模型中,患病和未切除的神经元的混合物不应导致非疾病神经元的疾病表型。最后,在两个热门模型中,细胞自主过程和细胞非自主过程可能会结合,以使表型的细胞自主倡议可以通过A或其他分泌的有毒介质来增强。我们建议通过进一步开发一个新的平台HIPSC人类神经元模型来开始测试这些想法。这些研究,如果成功的话,可以新阐明自主和非自主过程和两次打击模型的相对贡献。我们将使用由源自非饮食对照患者(NDC),FAD APPDP患者和SAD患者(称为SAD2)的HIPSC系列的神经元。我们有两个具体的实验目的:目标1)检验以下假设:在纯化的神经元中观察到的某些或所有缺陷,其中包含fad应用程序复制或来自SAD的个体SAD2个体的基因组,称为SAD2是细胞自主。目的2)检验以下假设:携带不同APOE等位基因的星形胶质细胞增强或抑制纯化神经元中的AD表型。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据

数据更新时间:2024-06-01

Lawrence S. Goldstein其他文献

Is Direct Collection of Pleural Fluid Into a Heparinized Syringe Important for Determination of Pleural pH?: A Brief Report
  • DOI:
    10.1378/chest.112.3.707
    10.1378/chest.112.3.707
  • 发表时间:
    1997-09-01
    1997-09-01
  • 期刊:
  • 影响因子:
  • 作者:
    Lawrence S. Goldstein;Kevin McCarthy;Atul C. Mehta;Alejandro C. Arroliga
    Lawrence S. Goldstein;Kevin McCarthy;Atul C. Mehta;Alejandro C. Arroliga
  • 通讯作者:
    Alejandro C. Arroliga
    Alejandro C. Arroliga
Avoiding Air in Pleural Fluid pH Samples
  • DOI:
    10.1378/chest.113.6.1730
    10.1378/chest.113.6.1730
  • 发表时间:
    1998-06-01
    1998-06-01
  • 期刊:
  • 影响因子:
  • 作者:
    Lawrence S. Goldstein;Alejandro C. Arroliga
    Lawrence S. Goldstein;Alejandro C. Arroliga
  • 通讯作者:
    Alejandro C. Arroliga
    Alejandro C. Arroliga
Methyl methanesulfonate-induced dominant lethal mutations in male mice detected in vitro
  • DOI:
    10.1016/s0027-5107(77)80017-1
    10.1016/s0027-5107(77)80017-1
  • 发表时间:
    1977-01-01
    1977-01-01
  • 期刊:
  • 影响因子:
  • 作者:
    Lawrence S. Goldstein
    Lawrence S. Goldstein
  • 通讯作者:
    Lawrence S. Goldstein
    Lawrence S. Goldstein
共 3 条
  • 1
前往

Lawrence S. Goldst...的其他基金

iPSC
诱导多能干细胞
  • 批准号:
    10407986
    10407986
  • 财政年份:
    2019
  • 资助金额:
    $ 21.38万
    $ 21.38万
  • 项目类别:
Elucidating AD genotype-phenotype relationships using genetics of human IPS cells
利用人类 IPS 细胞遗传学阐明 AD 基因型-表型关系
  • 批准号:
    8758050
    8758050
  • 财政年份:
    2014
  • 资助金额:
    $ 21.38万
    $ 21.38万
  • 项目类别:
Lab-on-a-chip Flow Cytometer Using COlor-Space-Time (COST) Coding Method
使用颜色时空 (COST) 编码方法的芯片实验室流式细胞仪
  • 批准号:
    8959759
    8959759
  • 财政年份:
    2014
  • 资助金额:
    $ 21.38万
    $ 21.38万
  • 项目类别:
Probing SORL1 Risk Factors with Human Induced Pluripotent Stem Cell Technology
利用人类诱导多能干细胞技术探索 SORL1 危险因素
  • 批准号:
    8676147
    8676147
  • 财政年份:
    2014
  • 资助金额:
    $ 21.38万
    $ 21.38万
  • 项目类别:
Lab-on-a-chip Flow Cytometer Using COlor-Space-Time (COST) Coding Method
使用颜色时空 (COST) 编码方法的芯片实验室流式细胞仪
  • 批准号:
    8780811
    8780811
  • 财政年份:
    2014
  • 资助金额:
    $ 21.38万
    $ 21.38万
  • 项目类别:
Testing cell autonomy of AD phenotypes using human IPS cells
使用人类 IPS 细胞测试 AD 表型的细胞自主性
  • 批准号:
    8384585
    8384585
  • 财政年份:
    2012
  • 资助金额:
    $ 21.38万
    $ 21.38万
  • 项目类别:
Pluripotent stem cell models of sporadic Alzheimer's Disease
散发性阿尔茨海默病的多能干细胞模型
  • 批准号:
    8029409
    8029409
  • 财政年份:
    2011
  • 资助金额:
    $ 21.38万
    $ 21.38万
  • 项目类别:
Pluripotent stem cell models of sporadic Alzheimer's Disease
散发性阿尔茨海默病的多能干细胞模型
  • 批准号:
    8321504
    8321504
  • 财政年份:
    2011
  • 资助金额:
    $ 21.38万
    $ 21.38万
  • 项目类别:
Human Stem Cell Model of Niemann Pick Type C
Niemann Pick C型人类干细胞模型
  • 批准号:
    7828398
    7828398
  • 财政年份:
    2010
  • 资助金额:
    $ 21.38万
    $ 21.38万
  • 项目类别:
Impairment of axonal transport by Amyloid precursor protein and amyloid Beta-prot
淀粉样前体蛋白和淀粉样β-prot对轴突运输的损害
  • 批准号:
    8132465
    8132465
  • 财政年份:
    2007
  • 资助金额:
    $ 21.38万
    $ 21.38万
  • 项目类别:

相似海外基金

Individual Predoctoral Fellowship
个人博士前奖学金
  • 批准号:
    10752036
    10752036
  • 财政年份:
    2024
  • 资助金额:
    $ 21.38万
    $ 21.38万
  • 项目类别:
Characterizing Entorhinal Cortex Circuit Dysfunction in an APOE Mouse Model of Chemotherapy-Induced Cognitive Impairment
化疗引起认知障碍的 APOE 小鼠模型中内嗅皮层回路功能障碍的特征
  • 批准号:
    10677984
    10677984
  • 财政年份:
    2023
  • 资助金额:
    $ 21.38万
    $ 21.38万
  • 项目类别:
Effects of Aging on Neuronal Lysosomal Damage Responses Driven by CMT2B-linked Rab7
衰老对 CMT2B 相关 Rab7 驱动的神经元溶酶体损伤反应的影响
  • 批准号:
    10678789
    10678789
  • 财政年份:
    2023
  • 资助金额:
    $ 21.38万
    $ 21.38万
  • 项目类别:
Neuronal ABCA7 loss of function and Alzheimer’s disease
神经元 ABCA7 功能丧失与阿尔茨海默病
  • 批准号:
    10629715
    10629715
  • 财政年份:
    2023
  • 资助金额:
    $ 21.38万
    $ 21.38万
  • 项目类别:
Uncovering the Role of the MS4A Gene Family in Alzheimer's Disease
揭示 MS4A 基因家族在阿尔茨海默病中的作用
  • 批准号:
    10751885
    10751885
  • 财政年份:
    2023
  • 资助金额:
    $ 21.38万
    $ 21.38万
  • 项目类别: